Advertisement

Therapeutic intervention on preformed anti-HLA antibodies

  • Fayçal Kriaa
  • Christian Hiesse
  • Sylvie Marchand
  • Christophe Goupy
  • Hossein Farahmand
  • Alain Bismuth
  • Gérard Benoit
  • Bernard M. Charpentier
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 29)

Abstract

The presence of broadly reactive antibodies directed at allogeneic lymphocytes is a major and increasing cause of delay in transplantation of patients with end-stage renal disease. In addition, hyperimmunized status is associated with a lower graft success rate that non-immunized status, unless patients were transplanted with excellent matched graft. Hyperimmunized patients represent an increasing proportion of graft waiting list, caused by previous graft failure, pregnancies and blood transfusions.

Keywords

ESRD Patient Hyperacute Rejection Idiotypic Network Humoral Rejection Positive Crossmatch 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Etablissement Français des Greffes, Rapport Annuel, 1995. Le prélèvement et la greffe en France en 1995.Google Scholar
  2. 2.
    Keown PA. The highly sensitized patient: aetiology, impact and management. Transplant. Proc. 1987; 19: 74–78.PubMedGoogle Scholar
  3. 3.
    Fuggle SV, Errasti P, Daar AS, Fabre JW, Ting A, Morris PJ. Localisation of MHC (HLA-ABC and DR) antigens in 46 kidneys. Differences in HLA-DR staining of tubules among kidneys. Transplantation 1983; 35: 385–390.PubMedCrossRefGoogle Scholar
  4. 4.
    Robinson MA, Kindt TJ. Major histocompatibility complex antigens and genes. In: Paul WE (ed.), Fundamental Immunology. New York, Raven Press, 1989, p. 489.Google Scholar
  5. 5.
    Chapman JR, Taylor CJ, Ting A, Morris PJ. Immunoglobulin class and specificity of antibodies causing positive T cell cross-matches. Transplantation 1986; 42: 608–613.PubMedCrossRefGoogle Scholar
  6. 6.
    Iwaki Y, Terasaki PI. Primary nonfunction in human cadaver kidney transplantation: evidence for hidden hyperacute rejection. Clin. Transplant. 1987; 1: 125–131.Google Scholar
  7. 7.
    Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, Palomaki GE, Hitchcox SA, White BW, Himmelfarb JJ, Leeber DA. The flow cytometric crossmatch and early renal transplant loss. Transplantation 1990; 49: 527–535.PubMedCrossRefGoogle Scholar
  8. 8.
    Alexandre GPJ, Squifflet JP, De Bruyere M, Latinne D, Moriau M, Carlier C, Pirson Y, Lecomte C. ABO-incompatible related and unrelated living donor renal allografts. Transplant. Proc. 1986; 18: 1090–1092.Google Scholar
  9. 9.
    Ferrara GB, Tosi M, Azzolina G, Carminati G, Longo A. HLA unresponsiveness induced by weekly transfusions of small aliquots of whole blood. Transplantation 1974; 17: 194–198.PubMedCrossRefGoogle Scholar
  10. 10.
    Rondeau E, Fournier A, Kanfer A, Sraer JD. Polyvalent immunoglobulins in sensitised renal transplant recipients. Nephrol. Dial. Transplant. 1991; 6: 675–676.PubMedGoogle Scholar
  11. 11.
    Cardella CJ, Nicholson MJ, Falk JA, Harding M, Cook GT. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet 1982; 2: 1240–1242.PubMedCrossRefGoogle Scholar
  12. 12.
    Taube DH, Welsh KI, Kennedy LA. Successful removal and prevention of resynthesis of anti-HLA antibody. Transplantation 1984; 34: 254–255.CrossRefGoogle Scholar
  13. 13.
    Hillebrand G, Castro LA, Samtleben W. Removal of preformed cytotoxic antibodies in highly sensitized patients using plasma exchange and immunosuppression therapy, azathioprine or cyclosporine prior to renal transplantation. Transplant. Proc. 1985; 17: 2501–2504.Google Scholar
  14. 14.
    Gjorstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfus. Sci. 1990; 11: 281–302.CrossRefGoogle Scholar
  15. 15.
    Palmer A, Taube D, Welsh K. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable transplantation. Lancet 1989; 1: 10–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Gjorstrup P for the Collaborative Study Group on Anti-HLA removal. Anti-HLA antibody removal in hyperimmunized ESRF patients to allow transplantation. Tranpslant. Proc. 1991; 23: 392–395.Google Scholar
  17. 17.
    Esnault V, Bignon JD, Testa. Effect of protein A immunoadsorption on panel lymphocyte reactivity in hyperimmunized patients awaiting a kidney graft. Transplantation 1990; 50: 449–453.PubMedCrossRefGoogle Scholar
  18. 18.
    Brocard JF, Farahmand H, Fassi S. Attempt at depletion of anti-HLA antibodies in sensitized patients awaiting transplantation using extracorporeal immunoadsorption, polyclonal IgG and immunosuppressive drugs. Transplant. Proc. 1989; 21: 733–734.PubMedGoogle Scholar
  19. 19.
    Kupin WL, Venkat KK, Hayaski H. Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 1991; 51: 324–329.PubMedCrossRefGoogle Scholar
  20. 20.
    Hakim RM, Milford E, Himmelfarb J. Extracorporeal removal of anti-HLA antibodies intransplant candidates. Am. J. Kidney Dis. 1990; 16: 423–432.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Fayçal Kriaa
  • Christian Hiesse
  • Sylvie Marchand
  • Christophe Goupy
  • Hossein Farahmand
  • Alain Bismuth
  • Gérard Benoit
  • Bernard M. Charpentier

There are no affiliations available

Personalised recommendations